These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1420 related items for PubMed ID: 28369471

  • 1. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1704-1708. PubMed ID: 28369471
    [Abstract] [Full Text] [Related]

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 01; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 3. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M, Monti G, Henriksen AS, Longshaw C.
    Antimicrob Resist Infect Control; 2024 Aug 26; 13(1):91. PubMed ID: 39183351
    [Abstract] [Full Text] [Related]

  • 4. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P.
    Eur J Clin Microbiol Infect Dis; 2017 Dec 26; 36(12):2319-2327. PubMed ID: 28748397
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF.
    Int J Antimicrob Agents; 2019 Feb 26; 53(2):177-184. PubMed ID: 30395986
    [Abstract] [Full Text] [Related]

  • 6. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M, Conejo MDC, Serrano L, Fernández-Cuenca F, Pascual Á.
    J Antimicrob Chemother; 2020 Jul 01; 75(7):1840-1849. PubMed ID: 32277821
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):380-386. PubMed ID: 30357343
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.
    J Glob Antimicrob Resist; 2024 Sep 01; 38():12-20. PubMed ID: 38789082
    [Abstract] [Full Text] [Related]

  • 9. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.
    Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, Domitrovic TN, Rudin SD, Richter SS, van Duin D, Kreiswirth BN, Greco C, Fouts DE, Bonomo RA.
    Antimicrob Agents Chemother; 2019 Jan 01; 63(1):. PubMed ID: 30323050
    [Abstract] [Full Text] [Related]

  • 10. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML, Caio C, Gona F, Cormaci R, Salerno I, Zingali T, Denaro C, Gennaro M, Quattrone C, Stefani S.
    Int J Antimicrob Agents; 2014 Aug 01; 44(2):112-6. PubMed ID: 25059444
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep 01; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Nov 01; 61(11):. PubMed ID: 28848004
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B, Goic-Barisic I, Budimir A, Tonkic M, Mihajkevic LJ, Novak A, Sviben M, Plecko V, Punda-Polic V, Kalenic S.
    J Chemother; 2010 Jun 01; 22(3):147-52. PubMed ID: 20566417
    [Abstract] [Full Text] [Related]

  • 14. Warning: spread of NDM-1 in two border towns of Iran.
    Armin S, Fallah F, Azimi L, Samadi Kafil H, Ghazvini K, Hasanzadeh S, Karimi A.
    Cell Mol Biol (Noisy-le-grand); 2018 Jul 30; 64(10):125-129. PubMed ID: 30084804
    [Abstract] [Full Text] [Related]

  • 15. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, Tsuji M, Yamano Y.
    J Antimicrob Chemother; 2018 Nov 01; 73(11):3049-3052. PubMed ID: 30188999
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates.
    Khanchandani H, Chaudhury M, Rao MS, Ramakrishna N, Venkataramana B, Chaudhury A.
    Indian J Med Microbiol; 2024 Nov 01; 48():100556. PubMed ID: 38447857
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).
    Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.
    Antimicrob Agents Chemother; 2017 Sep 01; 61(9):. PubMed ID: 28630181
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR, Adam HJ, Baxter M, Walkty A, Lagacé-Wiens P, Karlowsky JA, Zhanel GG.
    Diagn Microbiol Infect Dis; 2020 May 01; 97(1):115012. PubMed ID: 32081522
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
    Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.
    J Med Microbiol; 2017 Jan 01; 66(1):61-69. PubMed ID: 28051952
    [Abstract] [Full Text] [Related]

  • 20. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.
    Int J Antimicrob Agents; 2019 Apr 01; 53(4):456-466. PubMed ID: 30471402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.